Palvella Therapeutics, Inc.

PVLA Healthcare Biotechnology

Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.

EPS
−76.7%
Free cash flow
−136.4%

Quarter to June 2026, against a year earlier

174.08 17.23 +10.99%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
2/9
Altman Z
−11.49
Beneish M
1.44
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
66.94 58.99 263.23 253.03
Total non-current assets
— 0.57 0.53 0.48
Total Assets
66.94 59.56 263.76 253.51
Total current liabilities
10.31 11.34 9.12 11.95
Total non-current liabilities
17.94 20.23 22.33 24.70
Total liabilities
28.26 31.58 31.45 36.64
Common Equity (Total)
38.68 27.98 232.31 216.87
Shareholders Equity (Total)
38.68 27.98 232.31 216.87

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026